Blue Venture Fund and McKesson Ventures returned to reinvest in the cancer care analysis platform through a round that almost doubled its overall funding.

The diabetes treatment developer, which counts WL Gore and Johnson & Johnson as investors, has raised a further $27m for its latest round.

Philips Health Technology Ventures and UnityPoint Health Ventures have taken part in a $16.7m round for the telehealth technology provider.

Pharmaceuticals distributor MPharma increased its funding to more than $38m in a round that included Dompe Holdings.

A year after collecting $200m in series A funding, BGI gene sequencing spinoff MGI Tech has closed a $1bn series B round co-led by IDG Capital and CPE Capital.

Eli Lilly invested in AbCellera's series B round shortly after agreeing a research and collaboration licensing deal with the drug discovery technology provider.

Existing investor Novartis has committed to a $10m private placement alongside the IPO, in which the fibrosis therapy developer is set to raise up to $96m.

Axovant's seizure treatment spinoff has closed its series A round having received more than $133m in equity funding and $74.5m in project financing.

Eli Lilly, EMS, Takeda and ST Pharm are in line for exits after muscle disease therapy developer Avidity filed for a $100m initial public offering.

The oncology diagnostics technology provider has filed to go public in the US, with Legend Holdings and Eli Lilly set to exit through the flotation.